(Q35697573)

9 August 2017

1 reference

title

Delivering on the promise: HPV vaccines and cervical cancer (English)

1 reference

9 August 2017

1 reference

cervix uterine cancer

1 reference

John T Schiller

1

1 reference

9 August 2017

Philip Davies

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Nature Reviews Microbiology

9 August 2017

published in

1 reference

9 August 2017

volume

2

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

343-347

1 reference

The value of vaccination: a global perspective

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Human papillomavirus life cycle: active and latent phases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Awareness of human papillomavirus among women attending a well woman clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Production of human papillomavirus type 16 virus-like particles in transgenic plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Oral immunogenicity of human papillomavirus-like particles expressed in potato

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Chimeric papillomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Chapter 9: Role of mucosal human papillomavirus in nongenital cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Use of visual screening methods for cervical cancer screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Will New Human Papillomavirus Diagnostics Improve Cervical Cancer Control Efforts?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO867

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRMICRO867

1 reference

Dimensions Publication ID

9 August 2017

1036966892

0 references

1 reference